## Supplementary table 1. Flow chart.

| Study |  | Included in the study | Data on smoking, birth year, <br> and gender. No overlap <br> EIMS/GEMS. | Past smokers excluded | HLA genotype available. <br> Dataset for analysis. |
| :--- | :--- | :--- | :--- | :--- | :--- |
| EIMS | Cases | 2488 | 2488 | 2230 | 1626 |
|  | Controls | 6122 | 6122 | 4945 | 2295 |
| GEMS | Cases | 6156 | 6085 | 4983 | 4212 |
|  | Controls | 5408 | 5357 | 4405 | 3117 |
| Total | Cases | 9036 | 8965 | 7210 | 5838 |
|  | Controls | 11530 | 11479 | 9349 |  |

Supplementary table 2. OR with $95 \%$ CI of developing MS for subjects categorized by smoking and each of the HLA alleles associated with MS risk with a frequency exceeding 5\% among controls. Attributable proportion due to interaction between smoking and each of the HLA alleles.

| Interaction between smoking and DRB1*15:01 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Smoking | DRB1*15:01 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| - | - | 1324/2571 | 1.0 (reference) |  |
| - | + | 1888/1010 | 3.9 (3.2-4.3) |  |
| + | - | 1138/1325 | 1.6 (1.4-1.8) |  |
| + | + | 1488/506 | 6.5 (5.7-7.5) | 0.3 (0.2-0.4) |
| Interaction between smoking and absence of A*02:01 |  |  |  |  |
| Smoking | A*02:01 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| - | + | 1336/1959 | 1.0 (reference) |  |
| - | - | 1876/1622 | 1.7 (1.5-1.9) |  |
| + | + | 1146/1035 | 1.6 (1.4-1.8) |  |
| + | - | 1480/796 | 2.8 (2.3-2.9) | 0.2 (0.05-0.3) |
| Interaction between smoking and absence of B*44:02 |  |  |  |  |
| Smoking | B*44:02 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| - | + | 392/687 | 1.0 (reference) |  |
| - | - | 2820/2894 | 1.5 (1.3-1.7) |  |
| + | + | 362/341 | 1.9 (1.6-2.4) |  |


| + | - | $2264 / 1490$ | $2.3(2.0-2.6)$ | $-0.06(-0.2-0.1)$ |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Interaction between smoking and DRB1*03:01 |  |  |  |  |
| Smoking | DRB1*03:01 | ca/co $^{1}$ | OR (95\% CI) |  |

1number of exposed cases and controls; 2adjusted for age, gender, residential area, study, ancestry, rs 9277565, rs 2229092, DRB1*13:03, DRB1*08:01, B*38:01,
$\mathrm{B} * 55: 01, \mathrm{DQA} 1 * 01: 01, \mathrm{DQB} 1 * 03: 01$, and when appropriate for $\mathrm{DRB} 1 * 15: 01 . \mathrm{A} * 02: 01, \mathrm{~B} * 44: 02, \mathrm{DRB} 1 * 03: 01, \mathrm{DQB} 1 * 03: 02$, homozygote correction for

Supplementary table 3. OR with $95 \%$ CI of developing MS for subjects categorized by DRB1*15:01 and each of the other HLA alleles associated with MS risk with a frequency exceeding 5\% among controls. Attributable proportion due to interaction between DRB1*15:01 and each of the HLA alleles.

| Interaction between DRB1*15:01 and absence of A*02:01 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| DRB1*15:01 | A*02:01 | $\mathrm{ca} / \mathrm{cos}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| - | + | 973/2133 | 1.0 (reference) |  |
| - | - | 1489/1763 | 1.7 (1.5-1.9) |  |
| + | + | 1509/861 | 4.2 (3.7-4.8) |  |
| + | - | 1867/655 | 7.0 (6.0-8.0) | 0.3 (0.2-0.4) |
| Interaction between DRB1*15:01 and absence of B*44:02 |  |  |  |  |
| DRB1*15:01 | B*44:02 | $\mathrm{ca} / \mathrm{cos}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| - | + | 309/756 | 1.0 (reference) |  |
| - | - | 2153/3140 | 1.3 (1.1-1.6) |  |
| + | + | 445/272 | 4.1 (3.3-5.0) |  |
| + | - | 2931/1244 | 5.5 (4.7-6.6) | 0.2 (0.07-0.3) |
| Interaction between DRB1*15:01 and DRB1*03:01 |  |  |  |  |
| DRB1*15:01 | DRB1*03:01 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| - | - | 1746/2843 | 1.0 (reference) |  |
| - | + | 716/1053 | 0.9 (0.8-1.0) |  |
| + | - | 2915/1301 | 3.5 (3.2-3.9) |  |


| + | + | $461 / 215$ | $3.5(2.9-4.2)$ | $0.02(-0.2-0.2)$ |
| :--- | :--- | :--- | :--- | :--- | :--- |
| Interaction between DRB1*15:01 and DQB1*03:02 |  |  |  |  |
| DRB1*15:01 | DQB1*03:02 | ca/co $^{1}$ | OR (95\% CI) |  |
|  |  |  |  |  |
| + | + | $1660 / 2705$ | $1.0($ reference $)$ |  |
| + | - | $802 / 1191$ | $1.3(1.1-1.5)$ |  |
| - | + | $2839 / 1283$ | $3.6(3.2-4.0)$ |  |
| - | - | $537 / 233$ | $4.6(3.8-5.5)$ | $0.2(-0.03-0.3)$ |

1number of exposed cases and controls; 2adjusted for age, gender, residential area, study, ancestry, smoking, rs 9277565 , rs2229092, DRB1*13:03, DRB1*08:01, $B * 38: 01, B * 55: 01, D Q A 1 * 01: 01, D Q B 1 * 03: 01$, homozygote correction for DRB1*15:01, and when appropriate for A*02:01, B*44:02, DRB1*03:01, and

DQB1*03:02, homozygote correction for DRB1*03:01 and A*02:01.

Supplementary table 4. OR with $95 \%$ CI of developing MS for subjects categorized by A*02:01 and each of the other HLA alleles associated with MS risk with a frequency exceeding $5 \%$ among controls. Attributable proportion due to interaction between $A * 02: 01$ and each of the HLA alleles.

| Interaction between absence of A*02:01 and DRB1*15:01 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| A*02:01 | DRB1*15:01 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| + | - | 973/2133 | 1.0 (reference) |  |
| + | + | 1509/861 | 4.2 (3.7-4.8) |  |
| - | - | 1489/1763 | 1.7 (1.5-1.9) |  |
| - | + | 1867/655 | 7.0 (6.0-8.0) | 0.3 (0.2-0.4) |
| Interaction between absence of A*02:01 and absence of B*44:02 |  |  |  |  |
| A*02:01 | B*44:02 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| + | + | 426/723 | 1.0 (reference) |  |
| + | - | 2056/2271 | 1.4 (1.2-1.7) |  |
| - | + | 328/305 | 1.9 (1.5-2.3) |  |
| - | - | 3028/2113 | 2.4 (2.1-2.8) | 0.04 (-0.1-0.2) |
| Interaction between absence of A*02:01 and DRB1*03:01 |  |  |  |  |
| A*02:01 | DRB1*03:01 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| + | - | 2149/2423 | 1.0 (reference) |  |
| + | + | 333/571 | 0.9 (0.8-1.0) |  |


| - | - | $2512 / 1721$ | $1.7(1.5-1.8)$ |  |
| :--- | :--- | :--- | :--- | :--- |
| - | + | $844 / 697$ | $1.6(1.4-1.9)$ | $0.07(-0.08-0.2)$ |
| Interaction between absence of A*02:01 and DQB1*03:02 |  |  |  |  |
| A*02:01 | DQB1*03:02 | $\mathrm{ca}^{2}$ co $^{1}$ | OR (95\% CI) ${ }^{2}$ | AP |
| + | - | $1877 / 2146$ | $1.0($ reference $)$ |  |
| + | + | $605 / 848$ | $1.2(1.1-1.4)$ |  |
| - | - | $2622 / 1842$ | $1.7(1.5-1.9)$ |  |
| - | + | $734 / 576$ | $2.2(1.9-2.6)$ | $0.1(-0.003-0.3)$ |

1number of exposed cases and controls; 2adjusted for age, gender, residential area, study, ancestry, smoking, rs9277565, rs2229092, DRB1*15:01, DRB1*13:03,

DRB1*08:01, B*38:01, B*55:01, DQA1*01:01, DQB1*03:01, homozygote correction for DRB1*15:01, and A*02:01. and when appropriate for B*44:02,

DRB1*03:01, DQB1*03:02, homozygote correction for DRB1*03:01.

Supplementary table 5. OR with $95 \%$ CI among subjects with different combinations of DQA1*01:01 and DRB1*15:01, in total and stratified by smoking. Attributable proportion due to interaction between absence of DQA1*01:01 and DRB1*15:01.

|  |  |  | Total |  | Smokers |  | Never smokers |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| DQA1*01:01 | DRB1*15:01 | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{2}$ | OR (95\% CI) ${ }^{3}$ | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{3}$ | $\mathrm{ca} / \mathrm{co}^{1}$ | OR (95\% CI) ${ }^{3}$ |
| + | - | 752/1198 | 1.0 (reference) | 1.0 (reference) | 369/447 | 1.0 (reference) | 383/751 | 1.0 (reference) |
| - | - | 1710/2698 | 0.9 (0.8-1.1) | 0.9 (0.8-1.0) | 769/878 | 1.0 (0.8-1.2) | 941/1820 | 0.9 (0.8-1.1) |
| + | + | 314/239 | 2.5 (1.7-3.5) | 2.2 (1.8-2.8) | 122/77 | 2.1 (1.5-3.0) | 192/162 | 2.5 (1.9-3.2) |
| - | + | 3062/1277 | 3.5 (3.0-4.2) | 3.6 (3.2-4.1) | 1366/429 | 3.9 (3.2-4.7) | 1696/848 | 3.6 (3.1-4.2) |
|  |  |  |  | 0.4 (0.3-0.5) |  | 0.5 (0.3-0.6) |  | 0.3 (0.2-0.5) |

${ }^{1}$ exposed number of cases and controls; ${ }^{2}$ adjusted for age, gender, residential area, ancestry, and study; ${ }^{3}$ adjusted for age, gender, residential area, ancestry, study, A*0201, DRB1*0301, DRB1*1303, DRB1*0801, B*4402, B*3801, B*5501, DQA1*0101, DQB1*0301, DQB1*0302, homozygote correction for $\mathrm{DRB} 1 * 15, \mathrm{DRB} 1 * 0301$ and $\mathrm{A} * 0201 ; \mathrm{AP}=$ attributable proportion due to interaction.

